Svetlana Nikic: Can Concordance Between Liquid and Tissue Biopsies Change Outcomes?
Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn about a paper by Andrea Botticelli et al. published in Clinical Cancer Research:
“Can concordance between liquid and tissue biopsies change outcomes in precision oncology?
The exploratory analysis of the ROME Trial provides new insights. Among 1,794 patients with advanced solid tumors, NGS was performed on both tissue and liquid biopsies (LBx).
Key findings:
- Concordance rate: 49% – actionable alterations detected in both tissue and liquid biopsies.
- Patients with concordant results who received molecularly matched therapy (MMT) achieved significantly better outcomes vs. standard of care:
Median OS: 10.9 vs. 7.7 months
Median PFS: 4.9 vs. 2.8 months - The benefit of MMT was less pronounced or absent when results were discordant.
- Concordance emerged as a potential predictive biomarker for survival benefit in precision oncology.
Clinical relevance:
These results highlight the value of integrating both liquid and tissue biopsy profiling to optimize treatment selection. Concordant findings may identify patients most likely to benefit from targeted therapies, helping to refine precision medicine strategies.
This study reinforces the importance of combining diagnostic modalities rather than relying on one alone, paving the way for more effective, individualized cancer care.
(Some of the study limitations are: The analysis was exploratory, without predefined statistical power; About 20% of discordant cases were due to test failures; Subgroup sizes (especially liquid-only) were small, limiting robustness and biological and technical differences (e.g. ctDNA shedding, detection of amplifications, brain tumors) may have influenced discordance.
Amazing team effort – congratulation to many authors involved such as Paolo Marchetti, Andrea Botticelli!
Full paper available in Clinical Cancer Research.”
Title: The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial
Authors: Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, Mauro Biffoni, Sara Lonardi, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo Ascierto, Giovanni Blandino, Giulia d’Amati, Massimo Aglietta, Pierfranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea De Censi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Giuseppe Curigliano, Paolo Marchetti
More posts featuring Svetlana Nikic on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023